biology

Transgene (company)

Transgene (company) is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Transgene (company) rather than just read about it. In short: Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace.

Key takeaways

Transgene (company) belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Transgene (company) to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Transgene (company) from memory before moving on to harder problems.

Reference excerpt

Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells. Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses. Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer. The company is listed on the regulated market of Euronext in Paris.

History Transgene was founded in 1979, on the initiative of Pierre Chambon and Philippe Kourilsky. Jean-Pierre Lecocq was the first Scientific Director of Transgene in 1980. Dr Alessandro Riva, MD, joined Transgene in 2022 as Chairman of the Board of Directors. In May 2023 the board appointed him Chairman and Chief Executive Officer of the company,.

Technological platforms Transgene owns two technological platforms:

Invir.IO is a technology platform based on the patented oncolytic viruses that replicate only in cancer cells. The genome of these viruses has been modified to express anti-tumor therapies directly within the tumor. The myvac® platform is based on an MVA vector which safety, biological activity and ability to induce an immune response against tumor antigens are established and recognized. The platform enables the design of personalized viruses based on each patient's tumor mutations. Transgene selects around 30 neoantigens per patient, based on the AI of its partner NEC, and then encodes them into viral DNA.

Products in development The Company has several clinical-stage products in its portfolio. 1- TG4050 : This neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer. 2- TG4001 : is a therapeutic vaccine designed to express the E6 and E7 antigens of the HPV-16 virus (human papillomavirus type 16). Transgene is currently evaluating the full study results in detail to determine the best way forward for this program. 3- Oncolytic viruses: TG6050 and BT-001. Transgene's oncolytic viruses are designed to directly and selectively destroy the cancer cells by using an oncolysis mechanism, while also inducing immune responses against tumor cells. In addition, during their replication, the virus expresses the payloads integrated in its genome and therefore allows the expression of immunomodulators and/or therapeutic agents specifically in the tumors,,,,. 4- Transgene and AstraZeneca have been collaborating since 2019 to co-develop oncolytic viruses from the Invir.IO™ platform.

Management Committee Transgene's Management Committee is composed of the following members:

Alessandro Riva, Chairman & Chief Executive Officer (CEO) Hedi Ben Brahim, Chairman & Chief Executive Officer (CEO); Éric Quéméneur, Executive Vice-President, Chief Scientific Officer (CSO); Christophe Ancel, Vice-President Pharmaceutical Operations & Qualified Pharmacist; Maud Brandely-Talbot, Vice-President Medical Affairs, Chief Medical Officer (CMO); Jean-Philippe Del, Vice-President, Chief Financial Officer (CFO); Thibaut du Fayet, Vice-President Corporate Development; John Felitti, Vice-President, General Counsel, Corporate Secretary; Gaëlle Stadtler, Vice-President, Human Resources Director.

References

External links Official website

Worked examples

Example 1 — a first encounter with Transgene (company)

Start with the simplest possible case. Write down what Transgene (company) claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Transgene (company) before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Transgene (company) ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Transgene (company)

In research: Transgene (company) appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Transgene (company) in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Transgene (company) is common in secondary-school and first-year university syllabi. It links to neighbouring topics Biotechnology companies established in 1979, Biotechnology companies of France, Companies listed on Euronext Paris, so understanding it makes those chapters shorter.
In everyday life: Look for Transgene (company) outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Transgene (company)” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Transgene (company) in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Transgene (company) means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Transgene (company) out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Transgene (company) in simple terms?

Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace.

Why does Transgene (company) matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Transgene (company)?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Transgene (company).